Global Gemcitabine HCL Market By Product Type (Injection, Solution), By Indication (Breast Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Biliary Tract cancer, Others), By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific), Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2023 – 2031
Global Gemcitabine HCL Market was valued at US$ 674.2 Million in 2022, growing at an estimated CAGR of 7.2% from 2023-2031.
Gemcitabine HCL (Hydrochloride) is an anticancer drug used in chemotherapy to treat various types of cancer. It belongs to the class of nucleoside analogs and works by inhibiting DNA synthesis in rapidly dividing cancer cells, preventing their growth and proliferation. Gemcitabine is commonly used to treat pancreatic cancer, non-small cell lung cancer, breast cancer, and ovarian cancer. It is administered intravenously and is often combined with other chemotherapy drugs for a more effective treatment approach. Gemcitabine HCL has shown significant clinical benefits, including improved survival rates and symptom relief in cancer patients. However, like many chemotherapy drugs, it may also have side effects, and its usage is typically guided by an oncologist based on individual patient circumstances.
Gemcitabine HCL in the form of injections has been the dominant product type in the market. Injections are commonly used in chemotherapy treatments and are preferred for their ease of administration, precise dosage delivery, and faster onset of action. The widespread adoption of Gemcitabine HCL injections is attributed to their established efficacy and safety profiles in treating various types of cancer.
COVID-19 Analysis: Global Gemcitabine HCL Market
Healthcare systems around the world were primarily focused on managing COVID-19 cases, leading to a shift in priorities. Non-urgent medical procedures, including certain cancer treatments, were postponed or delayed to allocate resources to COVID-19 care. This change in focus might have impacted the administration of Gemcitabine HCL and other cancer treatments, affecting patient treatment schedules and outcomes.
Global Gemcitabine HCL Market Revenue & Forecast, (US$ Million), 2015 – 2031
A driver of the global gemcitabine HCL market is the rising incidence of cancer cases worldwide. According to the World Health Organization (WHO), cancer is one of the leading causes of morbidity and mortality, accounting for approximately 10 million deaths in 2021. The growing burden of cancer has driven the demand for effective chemotherapy treatments, including Gemcitabine HCL. As cancer cases continue to increase, the demand for Gemcitabine HCL and other oncology drugs is expected to rise to address the unmet medical needs and improve patient outcomes. A key restraint in the Gemcitabine HCL market is the patent expiry of branded formulations, leading to the entry of generic versions. As patents expire, generic manufacturers can enter the market, offering more affordable alternatives. According to the US Food and Drug Administration (FDA), the patent for Gemcitabine HCL injection expired in 2010. Generic competition can lead to price erosion, impacting the revenue of branded products and challenging market growth for the originator companies. This factor can limit revenue growth for the gemcitabine HCL market players.
Pancreatic cancer has been a dominating indication in the global gemcitabine HCL market. Gemcitabine HCL is commonly used as a first-line treatment for advanced or metastatic pancreatic cancer. Academic studies and clinical trials have highlighted its efficacy in improving survival rates and relieving symptoms in patients with this aggressive form of cancer.
North America dominated the global gemcitabine HCL market in 2022. The region's well-established healthcare infrastructures, high prevalence of cancer cases, and advanced research facilities have contributed to its dominant position. Academic studies and clinical trials in North America have extensively explored the use of Gemcitabine HCL in various cancer indications, further solidifying its prominence in the region.
Competitive Landscape
The report provides both, qualitative and quantitative research of global gemcitabine HCL market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global gemcitabine HCL market are
- Accord Healthcare Inc.
- Apotex Inc.
- Eli Lilly & Co.
- F. Hoffmann La Roche
- Fressenius Kabi USA
- Gland Pharma Ltd.
- Hebei Changsan Biochemical Pharmaceutical Co., Ltd
- Jiangsu Hansoh Pharmaceutical Group Co Ltd
- Mylan Pharmaceuticals Inc.
- Pfizer Inc. (Hospira Inc.)
- Sagent Pharmaceuticals Inc.
- Teva Pharmaceuticals Ltd.
- Other Industry Participants
Global Gemcitabine HCL Market:
By Product Type
- Injection
- Solution
By Indication
- Breast Cancer
- Non-small Cell Lung Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Biliary Tract cancer
- Others
By Region
- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2021
1.2.2. Base Year: 2022
1.2.3. Forecast Years: 2023 – 2031
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Gemcitabine HCL Market
6.
Market
Synopsis: Gemcitabine HCL Market
7.
Gemcitabine
HCL Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Gemcitabine HCL Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Gemcitabine HCL Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Gemcitabine HCL Market
7.8. PESTEL Analysis
8.
Global
Gemcitabine HCL Market Analysis and Forecasts, 2015 - 2022
8.1. Overview
8.1.1. Global Gemcitabine HCL Market Revenue (US$
Mn)
8.2. Global Gemcitabine HCL Market Revenue (US$
Mn) and Forecasts, By Product Type
8.2.1. Injection
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2022
8.2.1.3.
Market
Forecast, 2023 - 2031
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1.
Market
Estimation, 2015 - 2022
8.2.1.5.1.2.
Market
Forecast, 2023 - 2031
8.2.1.5.2.
Europe
8.2.1.5.2.1.
Market
Estimation, 2015 - 2022
8.2.1.5.2.2.
Market
Forecast, 2023 - 2031
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1.
Market
Estimation, 2015 - 2022
8.2.1.5.3.2.
Market
Forecast, 2023 - 2031
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1.
Market
Estimation, 2015 - 2022
8.2.1.5.4.2.
Market
Forecast, 2023 - 2031
8.2.1.5.5.
Latin
America
8.2.1.5.5.1.
Market
Estimation, 2015 - 2022
8.2.1.5.5.2.
Market
Forecast, 2023 - 2031
8.2.2. Solutions
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2022
8.2.2.3.
Market
Forecast, 2023 - 2031
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1.
Market
Estimation, 2015 - 2022
8.2.2.5.1.2.
Market
Forecast, 2023 - 2031
8.2.2.5.2.
Europe
8.2.2.5.2.1.
Market
Estimation, 2015 - 2022
8.2.2.5.2.2.
Market
Forecast, 2023 - 2031
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1.
Market
Estimation, 2015 - 2022
8.2.2.5.3.2.
Market
Forecast, 2023 - 2031
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1.
Market
Estimation, 2015 - 2022
8.2.2.5.4.2.
Market
Forecast, 2023 - 2031
8.2.2.5.5.
Latin
America
8.2.2.5.5.1.
Market
Estimation, 2015 - 2022
8.2.2.5.5.2.
Market
Forecast, 2023 - 2031
8.3. Key Segment for Channeling Investments
8.3.1. By Product Type
9.
Global
Gemcitabine HCL Market Analysis and Forecasts, 2015 - 2022
9.1. Overview
9.2. Global Gemcitabine HCL Market Revenue (US$
Mn) and Forecasts, By Indication
9.2.1. Breast Cancer
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2022
9.2.1.3.
Market
Forecast, 2023 - 2031
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1.
Market
Estimation, 2015 - 2022
9.2.1.5.1.2.
Market
Forecast, 2023 - 2031
9.2.1.5.2.
Europe
9.2.1.5.2.1.
Market
Estimation, 2015 - 2022
9.2.1.5.2.2.
Market
Forecast, 2023 - 2031
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1.
Market
Estimation, 2015 - 2022
9.2.1.5.3.2.
Market
Forecast, 2023 - 2031
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1.
Market
Estimation, 2015 - 2022
9.2.1.5.4.2.
Market
Forecast, 2023 - 2031
9.2.1.5.5.
Latin
America
9.2.1.5.5.1.
Market
Estimation, 2015 - 2022
9.2.1.5.5.2.
Market
Forecast, 2023 - 2031
9.2.2. Non-small Cell Lung Cancer
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2022
9.2.2.3.
Market
Forecast, 2023 - 2031
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1.
Market
Estimation, 2015 - 2022
9.2.2.5.1.2.
Market
Forecast, 2023 - 2031
9.2.2.5.2.
Europe
9.2.2.5.2.1.
Market
Estimation, 2015 - 2022
9.2.2.5.2.2.
Market
Forecast, 2023 - 2031
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1.
Market
Estimation, 2015 - 2022
9.2.2.5.3.2.
Market
Forecast, 2023 - 2031
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1.
Market
Estimation, 2015 - 2022
9.2.2.5.4.2.
Market
Forecast, 2023 - 2031
9.2.2.5.5.
Latin
America
9.2.2.5.5.1.
Market
Estimation, 2015 - 2022
9.2.2.5.5.2.
Market
Forecast, 2023 - 2031
9.2.3. Pancreatic Cancer
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2022
9.2.3.3.
Market
Forecast, 2023 - 2031
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North
America
9.2.3.5.1.1.
Market
Estimation, 2015 - 2022
9.2.3.5.1.2.
Market
Forecast, 2023 - 2031
9.2.3.5.2.
Europe
9.2.3.5.2.1.
Market
Estimation, 2015 - 2022
9.2.3.5.2.2.
Market
Forecast, 2023 - 2031
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1.
Market
Estimation, 2015 - 2022
9.2.3.5.3.2.
Market
Forecast, 2023 - 2031
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1.
Market
Estimation, 2015 - 2022
9.2.3.5.4.2.
Market
Forecast, 2023 - 2031
9.2.3.5.5.
Latin
America
9.2.3.5.5.1.
Market
Estimation, 2015 - 2022
9.2.3.5.5.2.
Market
Forecast, 2023 - 2031
9.2.4. Ovarian Cancer
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2015 - 2022
9.2.4.3.
Market
Forecast, 2023 - 2031
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1.
North
America
9.2.4.5.1.1.
Market
Estimation, 2015 - 2022
9.2.4.5.1.2.
Market
Forecast, 2023 - 2031
9.2.4.5.2.
Europe
9.2.4.5.2.1.
Market
Estimation, 2015 - 2022
9.2.4.5.2.2.
Market
Forecast, 2023 - 2031
9.2.4.5.3.
Asia
Pacific
9.2.4.5.3.1.
Market
Estimation, 2015 - 2022
9.2.4.5.3.2.
Market
Forecast, 2023 - 2031
9.2.4.5.4.
Middle
East and Africa
9.2.4.5.4.1.
Market
Estimation, 2015 - 2022
9.2.4.5.4.2.
Market
Forecast, 2023 - 2031
9.2.4.5.5.
Latin
America
9.2.4.5.5.1.
Market
Estimation, 2015 - 2022
9.2.4.5.5.2.
Market
Forecast, 2023 - 2031
9.2.5. Biliary Tract Cancer
9.2.5.1.
Definition
9.2.5.2.
Market
Estimation and Penetration, 2015 - 2022
9.2.5.3.
Market
Forecast, 2023 - 2031
9.2.5.4.
Compound
Annual Growth Rate (CAGR)
9.2.5.5.
Regional
Bifurcation
9.2.5.5.1.
North
America
9.2.5.5.1.1.
Market
Estimation, 2015 - 2022
9.2.5.5.1.2.
Market
Forecast, 2023 - 2031
9.2.5.5.2.
Europe
9.2.5.5.2.1.
Market
Estimation, 2015 - 2022
9.2.5.5.2.2.
Market
Forecast, 2023 - 2031
9.2.5.5.3.
Asia
Pacific
9.2.5.5.3.1.
Market
Estimation, 2015 - 2022
9.2.5.5.3.2.
Market
Forecast, 2023 - 2031
9.2.5.5.4.
Middle
East and Africa
9.2.5.5.4.1.
Market
Estimation, 2015 - 2022
9.2.5.5.4.2.
Market
Forecast, 2023 - 2031
9.2.5.5.5.
Latin
America
9.2.5.5.5.1.
Market
Estimation, 2015 - 2022
9.2.5.5.5.2.
Market
Forecast, 2023 - 2031
9.2.6. Others
9.2.6.1.
Definition
9.2.6.2.
Market
Estimation and Penetration, 2015 - 2022
9.2.6.3.
Market
Forecast, 2023 - 2031
9.2.6.4.
Compound
Annual Growth Rate (CAGR)
9.2.6.5.
Regional
Bifurcation
9.2.6.5.1.
North
America
9.2.6.5.1.1.
Market
Estimation, 2015 - 2022
9.2.6.5.1.2.
Market
Forecast, 2023 - 2031
9.2.6.5.2.
Europe
9.2.6.5.2.1.
Market
Estimation, 2015 - 2022
9.2.6.5.2.2.
Market
Forecast, 2023 - 2031
9.2.6.5.3.
Asia
Pacific
9.2.6.5.3.1.
Market
Estimation, 2015 - 2022
9.2.6.5.3.2.
Market
Forecast, 2023 - 2031
9.2.6.5.4.
Middle
East and Africa
9.2.6.5.4.1.
Market
Estimation, 2015 - 2022
9.2.6.5.4.2.
Market
Forecast, 2023 - 2031
9.2.6.5.5.
Latin
America
9.2.6.5.5.1.
Market
Estimation, 2015 - 2022
9.2.6.5.5.2.
Market
Forecast, 2023 - 2031
9.3. Key Segment for Channeling Investments
9.3.1. By Indication
10. North America Gemcitabine HCL Market
Analysis and Forecasts, 2023 - 2031
10.1. Overview
10.1.1. North America Gemcitabine HCL Market Revenue
(US$ Mn)
10.2. North America Gemcitabine HCL Market Revenue
(US$ Mn) and Forecasts, By Product Type
10.2.1. Injection
10.2.2. Solutions
10.3. North America Gemcitabine HCL Market Revenue
(US$ Mn) and Forecasts, By Indication
10.3.1. Breast Cancer
10.3.2. Non-small Cell Lung Cancer
10.3.3. Pancreatic Cancer
10.3.4. Ovarian Cancer
10.3.5. Biliary Tract Cancer
10.3.6. Others
10.4. North America Gemcitabine HCL Market Revenue
(US$ Mn) and Forecasts, By Country
10.4.1. U.S
10.4.1.1.
U.S
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
10.4.1.1.1.
Injection
10.4.1.1.2.
Solutions
10.4.1.2.
U.S
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
10.4.1.2.1.
Breast
Cancer
10.4.1.2.2.
Non-small
Cell Lung Cancer
10.4.1.2.3.
Pancreatic
Cancer
10.4.1.2.4.
Ovarian
Cancer
10.4.1.2.5.
Biliary
Tract Cancer
10.4.1.2.6.
Others
10.4.2. Canada
10.4.2.1.
Canada
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
10.4.2.1.1.
Injection
10.4.2.1.2.
Solutions
10.4.2.2.
Canada
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
10.4.2.2.1.
Breast
Cancer
10.4.2.2.2.
Non-small
Cell Lung Cancer
10.4.2.2.3.
Pancreatic
Cancer
10.4.2.2.4.
Ovarian
Cancer
10.4.2.2.5.
Biliary
Tract Cancer
10.4.2.2.6.
Others
10.4.3. Mexico
10.4.3.1.
Mexico
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
10.4.3.1.1.
Injection
10.4.3.1.2.
Solutions
10.4.3.2.
Mexico
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
10.4.3.2.1.
Breast Cancer
10.4.3.2.2.
Non-small
Cell Lung Cancer
10.4.3.2.3.
Pancreatic
Cancer
10.4.3.2.4.
Ovarian
Cancer
10.4.3.2.5.
Biliary
Tract Cancer
10.4.3.2.6.
Others
10.4.4. Rest of North America
10.4.4.1.
Rest of
North America Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product
Type
10.4.4.1.1.
Injection
10.4.4.1.2.
Solutions
10.4.4.2.
Rest of
North America Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By
Indication
10.4.4.2.1.
Breast
Cancer
10.4.4.2.2.
Non-small
Cell Lung Cancer
10.4.4.2.3.
Pancreatic
Cancer
10.4.4.2.4.
Ovarian
Cancer
10.4.4.2.5.
Biliary
Tract Cancer
10.4.4.2.6.
Others
10.5. Key Segment for Channeling Investments
10.5.1. By Country
10.5.2. By Product Type
10.5.3. By Indication
11. Europe Gemcitabine HCL Market Analysis and
Forecasts, 2023 - 2031
11.1. Overview
11.1.1. Europe Gemcitabine HCL Market Revenue (US$
Mn)
11.2. Europe Gemcitabine HCL Market Revenue (US$
Mn) and Forecasts, By Product Type
11.2.1. Injection
11.2.2. Solutions
11.3. Europe Gemcitabine HCL Market Revenue (US$
Mn) and Forecasts, By Indication
11.3.1. Breast Cancer
11.3.2. Non-small Cell Lung Cancer
11.3.3. Pancreatic Cancer
11.3.4. Ovarian Cancer
11.3.5. Biliary Tract Cancer
11.3.6. Others
11.4. Europe Gemcitabine HCL Market Revenue (US$
Mn) and Forecasts, By Country
11.4.1. France
11.4.1.1.
France
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
11.4.1.1.1.
Injection
11.4.1.1.2.
Solutions
11.4.1.2.
France
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
11.4.1.2.1.
Breast
Cancer
11.4.1.2.2.
Non-small
Cell Lung Cancer
11.4.1.2.3.
Pancreatic
Cancer
11.4.1.2.4.
Ovarian
Cancer
11.4.1.2.5.
Biliary
Tract Cancer
11.4.1.2.6.
Others
11.4.2. The UK
11.4.2.1.
The UK
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
11.4.2.1.1.
Injection
11.4.2.1.2.
Solutions
11.4.2.2.
The UK
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
11.4.2.2.1.
Breast
Cancer
11.4.2.2.2.
Non-small
Cell Lung Cancer
11.4.2.2.3.
Pancreatic
Cancer
11.4.2.2.4.
Ovarian
Cancer
11.4.2.2.5.
Biliary Tract
Cancer
11.4.2.2.6.
Others
11.4.3. Spain
11.4.3.1.
Spain
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
11.4.3.1.1.
Injection
11.4.3.1.2.
Solutions
11.4.3.2.
Spain
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
11.4.3.2.1.
Breast
Cancer
11.4.3.2.2.
Non-small
Cell Lung Cancer
11.4.3.2.3.
Pancreatic
Cancer
11.4.3.2.4.
Ovarian
Cancer
11.4.3.2.5.
Biliary
Tract Cancer
11.4.3.2.6.
Others
11.4.4. Germany
11.4.4.1.
Germany
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
11.4.4.1.1.
Injection
11.4.4.1.2.
Solutions
11.4.4.2.
Germany
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
11.4.4.2.1.
Breast
Cancer
11.4.4.2.2.
Non-small
Cell Lung Cancer
11.4.4.2.3.
Pancreatic
Cancer
11.4.4.2.4.
Ovarian
Cancer
11.4.4.2.5.
Biliary
Tract Cancer
11.4.4.2.6.
Others
11.4.5. Italy
11.4.5.1.
Italy
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
11.4.5.1.1.
Injection
11.4.5.1.2.
Solutions
11.4.5.2.
Italy
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
11.4.5.2.1.
Breast
Cancer
11.4.5.2.2.
Non-small
Cell Lung Cancer
11.4.5.2.3.
Pancreatic
Cancer
11.4.5.2.4.
Ovarian
Cancer
11.4.5.2.5.
Biliary
Tract Cancer
11.4.5.2.6.
Others
11.4.6. Nordic Countries
11.4.6.1.
Nordic
Countries Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product
Type
11.4.6.1.1.
Injection
11.4.6.1.2.
Solutions
11.4.6.2.
Nordic
Countries Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
11.4.6.2.1.
Breast
Cancer
11.4.6.2.2.
Non-small
Cell Lung Cancer
11.4.6.2.3.
Pancreatic
Cancer
11.4.6.2.4.
Ovarian
Cancer
11.4.6.2.5.
Biliary
Tract Cancer
11.4.6.2.6.
Others
11.4.6.3.
Nordic
Countries Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Country
11.4.6.3.1.
Denmark
11.4.6.3.2.
Finland
11.4.6.3.3.
Iceland
11.4.6.3.4.
Sweden
11.4.6.3.5.
Norway
11.4.7. Benelux Union
11.4.7.1.
Benelux
Union Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
11.4.7.1.1.
Injection
11.4.7.1.2.
Solutions
11.4.7.2.
Benelux
Union Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
11.4.7.2.1.
Breast
Cancer
11.4.7.2.2.
Non-small
Cell Lung Cancer
11.4.7.2.3.
Pancreatic
Cancer
11.4.7.2.4.
Ovarian
Cancer
11.4.7.2.5.
Biliary
Tract Cancer
11.4.7.2.6.
Others
11.4.7.3.
Benelux
Union Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Country
11.4.7.3.1.
Belgium
11.4.7.3.2.
The
Netherlands
11.4.7.3.3.
Luxembourg
11.4.8. Rest of Europe
11.4.8.1.
Rest of
Europe Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
11.4.8.1.1.
Injection
11.4.8.1.2.
Solutions
11.4.8.2.
Rest of
Europe Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
11.4.8.2.1.
Breast
Cancer
11.4.8.2.2.
Non-small
Cell Lung Cancer
11.4.8.2.3.
Pancreatic
Cancer
11.4.8.2.4.
Ovarian
Cancer
11.4.8.2.5.
Biliary
Tract Cancer
11.4.8.2.6.
Others
11.5. Key Segment for Channeling Investments
11.5.1. By Country
11.5.2. By Product Type
11.5.3. By Indication
12. Asia Pacific Gemcitabine HCL Market Analysis
and Forecasts, 2023 - 2031
12.1. Overview
12.1.1. Asia Pacific Gemcitabine HCL Market Revenue
(US$ Mn)
12.2. Asia Pacific Gemcitabine HCL Market Revenue
(US$ Mn) and Forecasts, By Product Type
12.2.1. Injection
12.2.2. Solutions
12.3. Asia Pacific Gemcitabine HCL Market Revenue
(US$ Mn) and Forecasts, By Indication
12.3.1. Breast Cancer
12.3.2. Non-small Cell Lung Cancer
12.3.3. Pancreatic Cancer
12.3.4. Ovarian Cancer
12.3.5. Biliary Tract Cancer
12.3.6. Others
12.4. Asia Pacific Gemcitabine HCL Market Revenue
(US$ Mn) and Forecasts, By Country
12.4.1. China
12.4.1.1.
China
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
12.4.1.1.1.
Injection
12.4.1.1.2.
Solutions
12.4.1.2.
China
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
12.4.1.2.1.
Breast
Cancer
12.4.1.2.2.
Non-small
Cell Lung Cancer
12.4.1.2.3.
Pancreatic
Cancer
12.4.1.2.4.
Ovarian
Cancer
12.4.1.2.5.
Biliary
Tract Cancer
12.4.1.2.6.
Others
12.4.2. Japan
12.4.2.1.
Japan
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
12.4.2.1.1.
Injection
12.4.2.1.2.
Solutions
12.4.2.2.
Japan
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
12.4.2.2.1.
Breast
Cancer
12.4.2.2.2.
Non-small
Cell Lung Cancer
12.4.2.2.3.
Pancreatic
Cancer
12.4.2.2.4.
Ovarian
Cancer
12.4.2.2.5.
Biliary
Tract Cancer
12.4.2.2.6.
Others
12.4.3. India
12.4.3.1.
India
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
12.4.3.1.1.
Injection
12.4.3.1.2.
Solutions
12.4.3.2.
India
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
12.4.3.2.1.
Breast
Cancer
12.4.3.2.2.
Non-small
Cell Lung Cancer
12.4.3.2.3.
Pancreatic
Cancer
12.4.3.2.4.
Ovarian
Cancer
12.4.3.2.5.
Biliary
Tract Cancer
12.4.3.2.6.
Others
12.4.4. New Zealand
12.4.4.1.
New
Zealand Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
12.4.4.1.1.
Injection
12.4.4.1.2.
Solutions
12.4.4.2.
New
Zealand Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
12.4.4.2.1.
Breast
Cancer
12.4.4.2.2.
Non-small
Cell Lung Cancer
12.4.4.2.3.
Pancreatic
Cancer
12.4.4.2.4.
Ovarian
Cancer
12.4.4.2.5.
Biliary
Tract Cancer
12.4.4.2.6.
Others
12.4.5. Australia
12.4.5.1.
Australia
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
12.4.5.1.1.
Injection
12.4.5.1.2.
Solutions
12.4.5.2.
Australia
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
12.4.5.2.1.
Breast
Cancer
12.4.5.2.2.
Non-small
Cell Lung Cancer
12.4.5.2.3.
Pancreatic
Cancer
12.4.5.2.4.
Ovarian
Cancer
12.4.5.2.5.
Biliary
Tract Cancer
12.4.5.2.6.
Others
12.4.6. South Korea
12.4.6.1.
South
Korea Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
12.4.6.1.1.
Injection
12.4.6.1.2.
Solutions
12.4.6.2.
South
Korea Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
12.4.6.2.1.
Breast
Cancer
12.4.6.2.2.
Non-small
Cell Lung Cancer
12.4.6.2.3.
Pancreatic
Cancer
12.4.6.2.4.
Ovarian
Cancer
12.4.6.2.5.
Biliary
Tract Cancer
12.4.6.2.6.
Others
12.4.7. Southeast Asia
12.4.7.1.
Southeast
Asia Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
12.4.7.1.1.
Injection
12.4.7.1.2.
Solutions
12.4.7.2.
Southeast
Asia Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
12.4.7.2.1.
Breast
Cancer
12.4.7.2.2.
Non-small
Cell Lung Cancer
12.4.7.2.3.
Pancreatic
Cancer
12.4.7.2.4.
Ovarian
Cancer
12.4.7.2.5.
Biliary
Tract Cancer
12.4.7.2.6.
Others
12.4.7.3.
Southeast
Asia Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Country
12.4.7.3.1.
Indonesia
12.4.7.3.2.
Thailand
12.4.7.3.3.
Malaysia
12.4.7.3.4.
Singapore
12.4.7.3.5.
Rest of
Southeast Asia
12.4.8. Rest of Asia Pacific
12.4.8.1.
Rest of
Asia Pacific Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product
Type
12.4.8.1.1.
Injection
12.4.8.1.2.
Solutions
12.4.8.2.
Rest of
Asia Pacific Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By
Indication
12.4.8.2.1.
Breast
Cancer
12.4.8.2.2.
Non-small
Cell Lung Cancer
12.4.8.2.3.
Pancreatic
Cancer
12.4.8.2.4.
Ovarian
Cancer
12.4.8.2.5.
Biliary
Tract Cancer
12.4.8.2.6.
Others
12.5. Key Segment for Channeling Investments
12.5.1. By Country
12.5.2. By Product Type
12.5.3. By Indication
13. Middle East and Africa Gemcitabine HCL
Market Analysis and Forecasts, 2023 - 2031
13.1. Overview
13.1.1. Middle East and Africa Gemcitabine HCL Market
Revenue (US$ Mn)
13.2. Middle East and Africa Gemcitabine HCL Market
Revenue (US$ Mn) and Forecasts, By Product Type
13.2.1. Injection
13.2.2. Solutions
13.3. Middle East and Africa Gemcitabine HCL Market
Revenue (US$ Mn) and Forecasts, By Indication
13.3.1. Breast Cancer
13.3.2. Non-small Cell Lung Cancer
13.3.3. Pancreatic Cancer
13.3.4. Ovarian Cancer
13.3.5. Biliary Tract Cancer
13.3.6. Others
13.4. Middle East and Africa Gemcitabine HCL Market
Revenue (US$ Mn) and Forecasts, By Country
13.4.1. Saudi Arabia
13.4.1.1.
Saudi
Arabia Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
13.4.1.1.1.
Injection
13.4.1.1.2.
Solutions
13.4.1.2.
Saudi
Arabia Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
13.4.1.2.1.
Breast
Cancer
13.4.1.2.2.
Non-small
Cell Lung Cancer
13.4.1.2.3.
Pancreatic
Cancer
13.4.1.2.4.
Ovarian
Cancer
13.4.1.2.5.
Biliary
Tract Cancer
13.4.1.2.6.
Others
13.4.2. UAE
13.4.2.1.
UAE
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
13.4.2.1.1.
Injection
13.4.2.1.2.
Solutions
13.4.2.2.
UAE
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
13.4.2.2.1.
Breast
Cancer
13.4.2.2.2.
Non-small
Cell Lung Cancer
13.4.2.2.3.
Pancreatic
Cancer
13.4.2.2.4.
Ovarian
Cancer
13.4.2.2.5.
Biliary
Tract Cancer
13.4.2.2.6.
Others
13.4.3. Egypt
13.4.3.1.
Egypt
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
13.4.3.1.1.
Injection
13.4.3.1.2.
Solutions
13.4.3.2.
Egypt
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
13.4.3.2.1.
Breast
Cancer
13.4.3.2.2.
Non-small
Cell Lung Cancer
13.4.3.2.3.
Pancreatic
Cancer
13.4.3.2.4.
Ovarian
Cancer
13.4.3.2.5.
Biliary
Tract Cancer
13.4.3.2.6.
Others
13.4.4. Kuwait
13.4.4.1.
Kuwait
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
13.4.4.1.1.
Injection
13.4.4.1.2.
Solutions
13.4.4.2.
Kuwait
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
13.4.4.2.1.
Breast
Cancer
13.4.4.2.2.
Non-small
Cell Lung Cancer
13.4.4.2.3.
Pancreatic
Cancer
13.4.4.2.4.
Ovarian
Cancer
13.4.4.2.5.
Biliary
Tract Cancer
13.4.4.2.6.
Others
13.4.5. South Africa
13.4.5.1.
South
Africa Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
13.4.5.1.1.
Injection
13.4.5.1.2.
Solutions
13.4.5.2.
South
Africa Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
13.4.5.2.1.
Breast
Cancer
13.4.5.2.2.
Non-small
Cell Lung Cancer
13.4.5.2.3.
Pancreatic
Cancer
13.4.5.2.4.
Ovarian
Cancer
13.4.5.2.5.
Biliary
Tract Cancer
13.4.5.2.6.
Others
13.4.6. Rest of Middle East & Africa
13.4.6.1.
Rest of
Middle East & Africa Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts,
By Product Type
13.4.6.1.1.
Injection
13.4.6.1.2.
Solutions
13.4.6.2.
Rest of
Middle East & Africa Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts,
By Indication
13.4.6.2.1.
Breast
Cancer
13.4.6.2.2.
Non-small
Cell Lung Cancer
13.4.6.2.3.
Pancreatic
Cancer
13.4.6.2.4.
Ovarian
Cancer
13.4.6.2.5.
Biliary
Tract Cancer
13.4.6.2.6.
Others
13.5. Key Segment for Channeling Investments
13.5.1. By Country
13.5.2. By Product Type
13.5.3. By Indication
14. Latin America Gemcitabine HCL Market
Analysis and Forecasts, 2023 - 2031
14.1. Overview
14.1.1. Latin America Gemcitabine HCL Market Revenue
(US$ Mn)
14.2. Latin America Gemcitabine HCL Market Revenue
(US$ Mn) and Forecasts, By Product Type
14.2.1. Injection
14.2.2. Solutions
14.3. Latin America Gemcitabine HCL Market Revenue
(US$ Mn) and Forecasts, By Indication
14.3.1. Breast Cancer
14.3.2. Non-small Cell Lung Cancer
14.3.3. Pancreatic Cancer
14.3.4. Ovarian Cancer
14.3.5. Biliary Tract Cancer
14.3.6. Others
14.4. Latin America Gemcitabine HCL Market Revenue
(US$ Mn) and Forecasts, By Country
14.4.1. Brazil
14.4.1.1.
Brazil
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
14.4.1.1.1.
Injection
14.4.1.1.2.
Solutions
14.4.1.2.
Brazil
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
14.4.1.2.1.
Breast
Cancer
14.4.1.2.2.
Non-small
Cell Lung Cancer
14.4.1.2.3.
Pancreatic
Cancer
14.4.1.2.4.
Ovarian
Cancer
14.4.1.2.5.
Biliary
Tract Cancer
14.4.1.2.6.
Others
14.4.2. Argentina
14.4.2.1.
Argentina
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product Type
14.4.2.1.1.
Injection
14.4.2.1.2.
Solutions
14.4.2.2.
Argentina
Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Indication
14.4.2.2.1.
Breast
Cancer
14.4.2.2.2.
Non-small
Cell Lung Cancer
14.4.2.2.3.
Pancreatic
Cancer
14.4.2.2.4.
Ovarian
Cancer
14.4.2.2.5.
Biliary
Tract Cancer
14.4.2.2.6.
Others
14.4.3. Rest of Latin America
14.4.3.1.
Rest of
Latin America Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By Product
Type
14.4.3.1.1.
Injection
14.4.3.1.2.
Solutions
14.4.3.2.
Rest of
Latin America Gemcitabine HCL Market Revenue (US$ Mn) and Forecasts, By
Indication
14.4.3.2.1.
Breast
Cancer
14.4.3.2.2.
Non-small
Cell Lung Cancer
14.4.3.2.3.
Pancreatic
Cancer
14.4.3.2.4.
Ovarian
Cancer
14.4.3.2.5.
Biliary
Tract Cancer
14.4.3.2.6.
Others
14.5. Key Segment for Channeling Investments
14.5.1. By Country
14.5.2. By Product Type
14.5.3. By Indication
15. Competitive Benchmarking
15.1. Brand Benchmarking
15.2. Market Share Analysis, 2022
15.3. Global Presence and Growth Strategies
15.3.1. Mergers and Acquisitions
15.3.2. Product Launches
15.3.3. Investments Trends
15.3.4. R&D Initiatives
16. Player Profiles
16.1. Accord Healthcare Inc.
16.1.1. Company Details
16.1.2. Company Overview
16.1.3. Product Offerings
16.1.4. Key Developments
16.1.5. Financial Analysis
16.1.6. SWOT Analysis
16.1.7. Business Strategies
16.2. Apotex Inc.
16.2.1. Company Details
16.2.2. Company Overview
16.2.3. Product Offerings
16.2.4. Key Developments
16.2.5. Financial Analysis
16.2.6. SWOT Analysis
16.2.7. Business Strategies
16.3. Eli Lilly & Co.
16.3.1. Company Details
16.3.2. Company Overview
16.3.3. Product Offerings
16.3.4. Key Developments
16.3.5. Financial Analysis
16.3.6. SWOT Analysis
16.3.7. Business Strategies
16.4. F. Hoffmann La Roche
16.4.1. Company Details
16.4.2. Company Overview
16.4.3. Product Offerings
16.4.4. Key Developments
16.4.5. Financial Analysis
16.4.6. SWOT Analysis
16.4.7. Business Strategies
16.5. Fressenius Kabi USA
16.5.1. Company Details
16.5.2. Company Overview
16.5.3. Product Offerings
16.5.4. Key Developments
16.5.5. Financial Analysis
16.5.6. SWOT Analysis
16.5.7. Business Strategies
16.6. Gland Pharma Ltd.
16.6.1. Company Details
16.6.2. Company Overview
16.6.3. Product Offerings
16.6.4. Key Developments
16.6.5. Financial Analysis
16.6.6. SWOT Analysis
16.6.7. Business Strategies
16.7. Hebei Changsan Biochemical Pharmaceutical
Co., Ltd
16.7.1. Company Details
16.7.2. Company Overview
16.7.3. Product Offerings
16.7.4. Key Developments
16.7.5. Financial Analysis
16.7.6. SWOT Analysis
16.7.7. Business Strategies
16.8. Jiangsu Hansoh Pharmaceutical Group Co Ltd
16.8.1. Company Details
16.8.2. Company Overview
16.8.3. Product Offerings
16.8.4. Key Developments
16.8.5. Financial Analysis
16.8.6. SWOT Analysis
16.8.7. Business Strategies
16.9. Mylan Pharmaceuticals Inc.
16.9.1. Company Details
16.9.2. Company Overview
16.9.3. Product Offerings
16.9.4. Key Developments
16.9.5. Financial Analysis
16.9.6. SWOT Analysis
16.9.7. Business Strategies
16.10. Pfizer Inc. (Hospira Inc.)
16.10.1. Company Details
16.10.2. Company Overview
16.10.3. Product Offerings
16.10.4. Key Developments
16.10.5. Financial Analysis
16.10.6. SWOT Analysis
16.10.7. Business Strategies
16.11. Sagent Pharmaceuticals Inc.
16.11.1. Company Details
16.11.2. Company Overview
16.11.3. Product Offerings
16.11.4. Key Developments
16.11.5. Financial Analysis
16.11.6. SWOT Analysis
16.11.7. Business Strategies
16.12. Teva Pharmaceuticals Ltd.
16.12.1. Company Details
16.12.2. Company Overview
16.12.3. Product Offerings
16.12.4. Key Developments
16.12.5. Financial Analysis
16.12.6. SWOT Analysis
16.12.7. Business Strategies
16.13. Other Market Participants
17. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.